API | viloxazine

viloxazine (Qelbree) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Viloxazine, sold under the brand name Qelbree and formerly as Vivalan among others, is a selective norepinephrine reuptake inhibitor medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form. ^Wikipedia

Chemistry

SMILES: CCOc1ccccc1OCC1CNCCO1
InChIKey: YWPHCCPCQOJSGZ-UHFFFAOYSA-N
Mol. Mass: 237.3
ALogP: 1.45 Partition coefficient
ChEMBL Molecules:

viloxazine

viloxazine hydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Sodium-dependent noradrenaline transporter (Homo sapiens) ^UniProt
- 5-hydroxytryptamine receptor 2B (Homo sapiens) ^UniProt
- 5-hydroxytryptamine receptor 2C (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (1)

Attention Deficit Disorder with Hyperactivity (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Alzheimer Disease (Early Phase 1)

Attention Deficit and Disruptive Behavior Disorders (Phase 4)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue